Intellia Therapeutics News and Activities

Intellia Therapeutics is one of the...

• Russell 3000;
• TOB Iconic 10,000.

Intellia Therapeutics is a company listed under the stock ticker NTLA (US).

View the org chart displaying its 36 main executives

Most searched biographies at Intellia Therapeutics

• John Leonard, President, Chief Executive Officer and Director
• Bill Chase, Director
• Jesse Goodman, Director

Popular executive movements at Intellia Therapeutics

• Maggie Sweeney, Director, Quality, has left the company  (posted on May 6 2026).

Create your alert
to follow the executive moves at Intellia Therapeutics.

Intellia Therapeutics has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Patrick Enright - Director at CuraSen Therapeutics

Learn more about the Biotechnology industry

Press releases by Intellia Therapeutics

• Intellia Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress - Intellia Therapeutics
• Press Releases - Intellia Therapeutics
• Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2022 Earnings and Company Updates - Intellia Therapeutics
• Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose - Intellia Therapeutic
• Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the International Liver Congress™ 2022 - Intellia Therapeutics
• Intellia Therapeutics Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress - Intellia Therapeutics
• Intellia Therapeutics Names Muna Bhanji, R.Ph., to its Board of Directors - Intellia Therapeutics
• Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its CRISPR-Engineered Allogeneic Platform at the 2022 Keystone Symposia’s Precision Genome Engineering Conference - Intellia Therapeutics
• Intellia Therapeutics Receives Authorization to Initiate Phase 1 Clinical Trial of NTLA-2001 for Transthyretin Amyloidosis (ATTR) | Intellia Therapeutics
• Intellia Therapeutics Congratulates Co-Founder Jennifer Doudna On Winning the 2020 Nobel Prize in Chemistry for Inventing the Revolutionary CRISPR/Cas9 Genome Editing Technology | Intellia Therapeutics
• View more press releases Close

Social media about Intellia Therapeutics

• Intellia Therapeutics on Wikipedia, Google News & Yahoo Finance
• Intellia Therapeutics on LinkedIn, X (Twitter) & YouTube